As the holidays approach, be mindful of the risks and rewards surrounding celebrations. With proactive measures and community support, it is possible to enjoy this festive season free from the shadows ...

(9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific ...

Wondering if Akeso is still a smart buy after its big run up, or if the best days are already priced in? You are not alone. That is exactly what we are going to unpack. The stock has cooled slightly ...

The “Gifting for Seniors” drive has been a yearly holiday event since 2020, but this is the most presents the program has ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

Netcare Akeso’s Crisis Line Manager, Megan Gonsalves, offers expert guidance for navigating the festive season when you’re on ...

Netcare Akeso’s Crisis Line Manager, Megan Gonsalves shares her essential mental health tips for navigating the festive ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with ...

Akeso, Inc. (9926.HK) (Akeso or the Company) announced that at the 2025 ESMO Asia Congress, updated results from the pivotal ...

The latest announcement is out from Akeso, Inc. ( (HK:9926) ).